Abstract
Oral route of administration continues to be the most preferred route among the different routes of administration of drugs due to various advantages including ease of ingestion, avoidance of pain, versatility and most importantly patient compliance. Immediate release tablets have gained popularity and acceptance as a drug delivery system, mainly because they are easy to administer and lead to better patient compliance. The present work involves the formulation development, optimization and in-vitro evaluation of immediate release Bromocriptine Mesylate tablets. To minimize critical process parameters and since Bromocriptine Mesylate is moisture and heat sensitive potent crystalline drug, direct compression method was selected for the formulation of immediate release tablets. Tablets were prepared containing Bromocriptine Mesylate, pharmatose DCL 21, starch, aerosil-200, magnessium stearate, sodium starch glycolate and cross carmellose sodium, in different concentrations. During the course of study it was found that the formulation F5 containing cross carmellose sodium as super disintegrant exhibited acceptable disintegration time, percentage drug content per tablet and In vitro drug release. So at last it was concluded that immediate release Bromocriptine Mesylate tablets containing pharmatose DCL 21 as diluent and 5% cross carmellose sodium as super disintegrant can be prepared using direct compression which met the required specifications.